Citations 33
A Pilot Study of Intensified PEG-Asparaginase in High-risk Acute Lymphoblastic Leukemia: Children’s Oncology Group Study AALL08P1
Rodriguez, Vilmarie , Kairalla, John A. , Salzer, Wanda L. , Raetz, Elizabeth A. , Loh, Mignon L. , Carroll, Andrew J. , Heerema, Nyla A. , Borowitz, Michael J., Asselin, Barbara L. , Carroll, William L. , Dreyer, ZoAnn E., Wood, Brent L. , Burke, Michael J , Devidas, Meenakshi , Winick, Naomi Joan , Hunger, Stephen P. , Dreyer, ZoAnn E. , Loh, Mignon L
Journal of Pediatric Hematology/Oncology | June 14, 2016 | Volume: 38 | Issue: 6 | Pages: 409-417
AALL08P1 was designed to determine whether biweekly intensified pegaspargase (I-PEG) was feasible and safe in pediatric patients with newly diagnosed high-risk B-precursor lymphoblastic leukemia when given with Children’s Oncology Group hemiaugmented BFM therapy. High-risk average (HR-Avg) patients received standard pegaspargase dosing (6 doses), whereas high-risk high (HR-High) patients received I-PEG biweekly from the start of Consolidation until day 1 of Maintenance. Feasibility and safety were defined in advance as ≥65% of patients tolerating at least 8 doses of I-PEG and 90% requiring ≤49 weeks from day 1 of Consolidation to the initiation of Maintenance. Targeted toxicities included allergic reactions, anaphylaxis, pancreatitis, thrombosis, bleeding, central nervous system events, and sepsis. AALL08P1 enrolled 104 patients; 54 were classified as HR-Avg and 30 as HR-High after completion of induction therapy. Only 53% (16/30) of the HR-High patients received ≥8 total doses of I-PEG and 50% (15/30) took ≤49 weeks from start of Consolidation to the initiation of Maintenance. I-PEG did not significantly increase grade 2 to 5 targeted toxicities. I-PEG was not feasible or safe as defined in AALL08P1. Complete assessment of this regimen was limited due to removal of patients from I-PEG regimen and early closure of the study.
A phase 1 dosing study of ruxolitinib in children with relapsed or refractory solid tumors, leukemias, or myeloproliferative neoplasms: A Children's Oncology Group phase 1 consortium study (ADVL1011)
Loh, Mignon L. , Brown, Patrick A. , Magoon, Daniel, Chen, Xuejun , Ahern, Charlotte H., Weigel, Brenda J. , Blaney, Susan M. , Reid, Joel M. , Tasian, Sarah K. , Rabin, Karen R. , Loh, Mignon L
Pediatric Blood & Cancer | May 13, 2015 | Volume: 62 | Issue: 10 | Pages: 1717-1724
A genome-wide association study of susceptibility to acute lymphoblastic leukemia in adolescents and young adults
Pérez-Andreu, Virginia, Zhang, Hui , Harvey, Richard C. , Payne-Turner, Debbie , Cheng, I-Ming, Carroll, William L. , Heerema, Nyla A. , Carroll, Andrew J. , Raetz, Elizabeth A. , Marcucci, Guido , Bloomfield, Clara D. , Mrózek, Krzysztof , Kohlschmidt, Jessica, Konopleva, Marina , Paietta, Elisabeth , Rowe, Jacob M. , Luger, Selina M. , Tallman, Martin S. , Dean, Michael , Torgerson, Dara G., Wang, Yanli , Relling, Mary V. , Evans, William E. , Gerhard, Daniela S., Loh, Mignon L. , Mullighan, Charles G. , Roberts, Kathryn G. , Xu, Heng Yi , Smith, Colton J. , Yang, Wenjian , Devidas, Meenakshi , Gastier‐Foster, Julie M. , Stock, Wendy , Kornblau, Steven M. , Burchard, Esteban G. , Yue, Feng , Pui, Ching-Hon , Jeha, Sima , Willman, Cheryl L. , Hunger, Stephen P. , Yang, Jun J.J. , Mullighan, Charles G , Harvey, Richard , Loh, Mignon L , Dean, Michael
Blood | December 3, 2014 | Volume: 125 | Issue: 4 | Pages: 680-686
Key PointsIn this first ALL GWAS in AYAs, we determined that inherited GATA3 variants strongly influence ALL susceptibility in this age group. These findings revealed similarities and differences in the genetic basis of ALL susceptibility between young children and AYAs.